Physician profile
John B Averette
NPI 1366477390
$1,661.37
in general payments reported to CMS, 2019-2025
17 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $84.23 · 2021: $152 · 2022: $316 · 2023: $228 · 2024: $616 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $333.74 | 2020-2025 | Skyrizi, Rinvoq, Mavyret |
| Phathom Pharmaceuticals, INC. | $324.95 | 2024-2025 | Voquezna |
| Genzyme Corporation | $153.07 | 2024-2025 | |
| Gilead Sciences, INC. | $122.73 | 2020-2025 | |
| Pfizer INC. | $117.64 | 2019-2024 | |
| Intra-Sana Laboratories | $116.08 | 2022 | |
| Janssen Biotech, INC. | $107.71 | 2020-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $90.60 | 2019-2020 | |
| Celgene Corporation | $72.09 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.36 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $33.78 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $30.84 | 2022-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $28.88 | 2019 | |
| Amgen INC. | $19.48 | 2025 | |
| Braintree Laboratories, INC. | $17.47 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $14.67 | 2025 | Zenpep |
| Enterra Medical, INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Averette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.